{
    "root": "fcfe3e97-071d-44d8-8235-bb6b67567c18",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CEREBYX",
    "value": "20250518",
    "ingredients": [
        {
            "name": "FOSPHENYTOIN SODIUM",
            "code": "7VLR55452Z"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TROMETHAMINE",
            "code": "023C2WHX2V"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "cerebyx indicated treatment generalized tonic-clonic status epilepticus prevention treatment seizures occurring neurosurgery . cerebyx also substituted , short-term , oral phenytoin . cerebyx used oral phenytoin possible [ ( 2.4 ) ( 5.2 ) ] .",
    "contraindications": "• dose , concentration , infusion rate cerebyx always expressed phenytoin sodium equivalents ( pe ) ( 2.1 ) • status epilepticus : adult loading dose 15 20 mg pe/kg rate 100 150 mg pe/min ( 2.3 ) pediatric loading dose 15 20 mg pe/kg rate 2 mg pe/kg/min ( 150 mg pe/min , whichever slower ) ( 2.3 ) • non-emergent loading maintenance dosing : adult loading dose 10 20 mg pe/kg given iv im ; initial maintenance dose 4 6 mg pe/kg/day divided doses ( 2.4 ) pediatric loading dose 10 15 mg pe/kg rate 1 2 mg pe/kg/min ( 150 mg pe/min , whichever slower ) ; initial maintenance dose 2 4 mg pe/kg every 12 hours rate 1 2 mg pe/kg/min ( 100 mg pe/min , whichever slower ) ( 2.4 ) • intramuscular : cerebyx ordinarily given intramuscularly ( 2.3 , 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "cerebyx contraindicated patients : •a history hypersensitivity cerebyx inactive ingredients , phenytoin hydantoins [ ( 5.6 ) ] . included angioedema . •sinus bradycardia , sino-atrial block , second third degree a-v block , adams-stokes syndrome effect parenteral phenytoin cerebyx ventricular automaticity . •a history prior acute hepatotoxicity attributable cerebyx phenytoin [ ( 5.8 ) ] . •coadministration delavirdine potential loss virologic response possible resistance delavirdine class non-nucleoside reverse transcriptase inhibitors .",
    "indications_original": "CEREBYX is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. CEREBYX can also be substituted, short-term, for oral phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].",
    "contraindications_original": "• The dose, concentration, and infusion rate of CEREBYX should always be expressed as phenytoin sodium equivalents (PE) ( 2.1 ) • For Status Epilepticus: o Adult loading dose is 15 to 20 mg PE/kg at a rate of 100 to 150 mg PE/min ( 2.3 ) o Pediatric loading dose is 15 to 20 mg PE/kg at a rate of 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower) ( 2.3 ) • For Non-emergent Loading and Maintenance Dosing: o Adult loading dose is 10 to 20 mg PE/kg given IV or IM; initial maintenance dose is 4 to 6 mg PE/kg/day in divided doses ( 2.4 ) o Pediatric loading dose is 10 to 15 mg PE/kg at a rate of 1 to 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower); initial maintenance dose is 2 to 4 mg PE/kg every 12 hours at a rate of 1 to 2 mg PE/kg/min (or 100 mg PE/min, whichever is slower) ( 2.4 ) • Intramuscular Administration: o CEREBYX should ordinarily not be given intramuscularly ( 2.3 , 2.4 )",
    "adverseReactions_original": "CEREBYX is contraindicated in patients with:\n                  \n                     \n                        •A history of hypersensitivity to CEREBYX or its inactive ingredients, or to phenytoin or other hydantoins [see Warnings and Precautions (5.6)]. Reactions have included angioedema.\n                     \n                        •Sinus bradycardia, sino-atrial block, second and third degree A-V block, or Adams-Stokes syndrome because of the effect of parenteral phenytoin or CEREBYX on   ventricular automaticity.\n                     \n                        •A history of prior acute hepatotoxicity attributable to CEREBYX or phenytoin [see Warnings and Precautions (5.8)].\n                     \n                        •Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors."
}